NCT06400940View on ClinicalTrials.gov

Prospective, Post-registration, Interventional, Randomized, in Parallel Groups, Multicenter Eurasian Clinical Study of DERIVO®/DERIVO® Mini Aneurysm Embolization Device, Europe-Asia

PHASE4RecruitingINTERVENTIONAL
Enrollment

640

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

August 17, 2026

Study Completion Date

August 31, 2028

Conditions
Intracranial Aneurysm
Interventions
DRUG

ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).

Antiplatelet (antithrombotic) monotherapy, including ticagrelor (tablets, 180 mg) or prasugrel (tablets, 10 mg).

DRUG

combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).

Double antiplatelet (antithrombotic) therapy (DAT), including a combination of clopidogrel (tablets, 75 mg) and acetylsalicylic acid (ASA, tablets, 100 mg) or a combination of ticagrelor (tablets, 180 mg) and ASA (tablets, 100 mg).

Trial Locations (1)

197341

RECRUITING

V.A. Almazov Fnmrc, Saint Petersburg

All Listed Sponsors
lead

Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health

OTHER